FSSAI-AYUSH dual compliance raises nutraceutical entry barriers

Food Safety and Standards Authority of India (FSSAI) and Ministry of AYUSH requirements raise nutraceutical entry barriers when food-classified Ayurvedic products must meet both frameworks. The industry assessment rates regulatory uncertainty and compliance complexity high for one to two years and three to four years, while India’s Ayurvedic products market is projected to grow at a 19.3% compound annual growth rate between 2022 and 2028.

How does FSSAI-AYUSH dual compliance raise entry barriers?

FSSAI-AYUSH dual compliance raises entry barriers because a food-classified Ayurvedic product can require food-safety controls alongside traditional-medicine manufacturing standards. FSSAI nutraceutical regulations require central licensing, approved ingredient schedules, labelling norms and substantiation of health claims, and prohibit disease-cure claims. AYUSH standards under the Drugs and Cosmetics Act require Good Manufacturing Practices (GMP), formulation standards, stability testing and documentation for traditional formulations.

The regulatory burden begins with product classification rather than ending with a licence. The Central Drugs Standard Control Organisation is identified in the source as providing clarification and post-market surveillance for products on the food-drug boundary. For food-classified Ayurvedic products, FSSAI-AYUSH dual compliance means that ingredient selection, formulation, labels and promotional claims must fit the relevant food and traditional-medicine requirements.

The source rates regulatory uncertainty and compliance complexity high in the one-to-two-year period and again in years three to four for both nutraceuticals and Ayurveda. The assessment rates the issue moderate in the five-to-seven-year period as standards mature. That outlook supports the conclusion that entry depends on maintaining systems through evolving guidelines, rather than completing a one-time approval process.

What capabilities do manufacturers need for FSSAI-AYUSH dual compliance?

Manufacturers need controlled production, testing and recordkeeping because FSSAI-AYUSH dual compliance connects market access with quality systems, label controls and claim support. Schedule M and World Health Organization Good Manufacturing Practices (WHO-GMP) cover manufacturing hygiene, validation protocols, quality-management systems and third-party audits. The source identifies investment in compliant facilities, technical and quality personnel, formulation development and continuing regulatory administration as requirements for regulated nutraceutical and Ayurvedic formulations.

Quality assurance also extends to independently assessed facilities. The Quality Council of India provides National Accreditation Board for Certification Bodies-accredited quality and GMP audits for food, nutraceutical and AYUSH manufacturing facilities. These audit and documentation requirements can help establish readiness for institutional procurement and export markets, but they add fixed costs for manufacturers that do not already have testing and quality-control infrastructure.

Claims and digital operations create additional compliance layers. FSSAI-AYUSH oversight includes scrutiny of advertising that implies a cure, a guaranteed result or a medical treatment outcome. The Indian Council of Medical Research-National Institute of Nutrition framework sets Recommended Dietary Allowance norms relevant to nutraceutical formulation and labelling, while the Digital Personal Data Protection Rules, 2025 set data-governance and security requirements for digital sales, teleconsultation and consumer-engagement systems.

Why could FSSAI-AYUSH dual compliance accelerate consolidation?

FSSAI-AYUSH dual compliance could accelerate consolidation because recurring costs for GMP, traceability, testing, documentation and claim review are harder for smaller and unorganised participants to absorb. The supplied industry analysis says quality standardisation, traceability and formalisation can pressure smaller participants in the short term while supporting long-term consolidation and improved monitoring. It describes the nutraceutical and Ayurvedic markets as fragmented by unorganised participants, regional formulations and multinational entrants.

The source classifies entry barriers in regulated nutraceutical and Ayurvedic formulations as moderate to high. It identifies compliant facilities, qualified personnel, formulation development and ongoing compliance as required investments, while acceptance among practitioners and institutional customers can lengthen entry timelines. Larger manufacturers can spread these fixed requirements over broader production and distribution, although that advantage depends on maintaining product consistency and meeting changing labelling and validation expectations.

Raw-material sourcing can reinforce the same divide. The source identifies seasonal herbs, imported botanicals and inconsistent ingredient quality as procurement vulnerabilities, with high impact in both the one-to-two-year and three-to-four-year periods. Contract farming, cultivation incentives, supplier diversification and backward integration are described as mechanisms that could moderate this pressure over five to seven years, but each requires capital, supplier relationships or both.

Which policies could offset compliance costs for smaller manufacturers?

Government programmes can lower part of the infrastructure burden, although they do not remove FSSAI-AYUSH standards. The AYUSH Manufacturing Promotion Scheme is intended to develop common manufacturing and testing infrastructure for AYUSH micro, small and medium enterprises, with emphasis on GMP, quality assurance and backward integration. The Production Linked Incentive schemes for food processing cover nutraceuticals, fortified foods and herbal formulations and are intended to support capacity expansion and technology upgrades.

The PM Formalisation of Micro Food Processing Enterprises programme offers credit-linked subsidies, skill development and export facilitation for micro food and nutraceutical businesses. These measures are relevant because the source reports that AYUSH-related micro, small and medium enterprises increased from 38,216 units in August 2021 to 53,023 units in January 2023. Common testing infrastructure and formalisation support could therefore affect how widely smaller producers can meet documentation and quality requirements.

The addressable market is expanding alongside these compliance demands. India’s Ayurvedic products market was Rs 62,600 crore in 2022 and is projected to reach Rs 1,82,400 crore in 2028, according to the source’s 19.3% annual growth estimate. AYUSH and herbal-product exports rose from Rs 5,580 crore in FY24 to Rs 5,907 crore in FY25, with 21.46% volume growth and 5.86% value growth, making quality certification and export-oriented manufacturing relevant beyond domestic sales.

Conclusion

FSSAI-AYUSH dual compliance makes compliance infrastructure a competitive requirement for food-classified Ayurvedic nutraceuticals. Central licensing, ingredient schedules, GMP, stability testing, labelling, health-claim substantiation and documentation create a cumulative threshold that can favour organised manufacturers with testing capacity, technical personnel and traceable supply chains. The source supports consolidation as a possible outcome of formalisation, not as a guaranteed market result.

The next factor to watch is whether the AYUSH Manufacturing Promotion Scheme, food-processing incentives and PM Formalisation of Micro Food Processing Enterprises support wider access to compliant manufacturing and testing capacity. Regulatory complexity is assessed as high through the three-to-four-year period, while clarification of food-drug boundary products by the Central Drugs Standard Control Organisation and implementation of the Digital Personal Data Protection Rules, 2025 will influence the compliance cost for product launches and digital distribution.